admin – Page 2678 – Get News Story

Narcolepsy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts| Taisho Pharmaceutical, Jazz Pharma, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical

The Key Narcolepsy Companies in the market include – NLS Pharmaceutics, Suven Life SciencesAlkermes, Inc., Jazz Pharmaceuticals, Taisho Pharmaceutical, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical, Theranexus, NLS Pharmaceutics, Axsome Therapeutics, Inc, Takeda, Pfizer, Avadel, Balance Therapeutics, and others.

DelveInsight’s “Narcolepsy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Narcolepsy, historical and forecasted epidemiology as well as the Narcolepsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Narcolepsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Narcolepsy Market Forecast

Some of the key facts of the Narcolepsy Market Report:

The Narcolepsy market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
In June 2025, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has unveiled new Phase 4 findings highlighting the effectiveness of Xywav® (a low-sodium oxybate formulation containing calcium, magnesium, potassium, and sodium) in treating individuals with narcolepsy. The results are part of four late-breaking abstracts from Jazz presented as oral sessions at SLEEP 2025, all of which were chosen by the Associated Professional Sleep Societies (APSS) for their scientific significance and innovation. Xywav remains the only FDA-approved low-sodium oxybate therapy for managing cataplexy or excessive daytime sleepiness (EDS) in narcolepsy patients aged 7 and older, as well as for adults with idiopathic hypersomnia. The recommended dosage ranges from 6 to 9 grams per night.
In May 2025, Takeda (TSE: 4502/NYSE: TAK) announced that the New England Journal of Medicine has published results from a Phase 2b trial evaluating oveporexton (TAK-861) in individuals with narcolepsy type 1 (NT1). Oveporexton is an investigational oral therapy that selectively targets orexin receptor 2 (OX2R) to restore orexin signaling, which is deficient in NT1. The trial results showed significant improvements in both objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy episodes, and meaningful improvements in overall disease severity and quality of life across all tested doses when compared to placebo after eight weeks of treatment.
In May 2025, A recent Phase IIb clinical trial highlighted encouraging results for Takeda’s oral orexin receptor 2 (OX2R)-selective agonist in treating narcolepsy type 1 (NT1). Published in the New England Journal of Medicine, the data indicates that oveporexton (TAK-861) notably reduced disease severity and helped participants achieve wakefulness levels close to normal. Takeda reports that the therapy is intended to target the core issue in NT1—orexin deficiency—in this long-term neurological disorder.
According to Slowik et al. (2022), narcolepsy type 1 has a prevalence of 14 per 100,000 people, while narcolepsy type 2 affects 65.4 per 100,000 people. The condition is most commonly diagnosed in late teens to early twenties and is 50% more prevalent among females in the US, based on data from 2008─2010.
According to Imanishi et al. (2022), a Japanese study using a health insurance claims database found that the overall annual prevalence of narcolepsy increased from 5.7 to 18.5 per 100,000 persons between 2010 and 2019. The largest increases were observed in patients aged 20–29 years and 10–19 years, with the highest prevalence in 2019 being 9.7–37.5 per 100,000 persons and 5.0–27.1 per 100,000 persons, respectively.
In the United States, narcolepsy is thought to afflict 1 in every 2,000 persons, according to the Narcolepsy Network Organisation. In contrast to paediatrics, adults are more often than children to suffer from narcolepsy, a sleep disease that is underdiagnosed
Slowik et al. (2022) estimate that the prevalence of narcolepsy type 1 is 14 per 100,000 people and type 2 is 65.4 per 100,000. According to research from 2008 to 2010, it is most prevalent in those who are in their late teens or early twenties, with a 50% greater female preponderance
Imanishi et al. (2022) in a Japanese study, which employed a health insurance claims database, found that in 2010 and 2019, the overall yearly prevalence climbed from 5.7 to 18.5/100,000 people
Key Narcolepsy Companies: NLS Pharmaceutics, Suven Life SciencesAlkermes, Inc., Jazz Pharmaceuticals, Taisho Pharmaceutical, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical, Theranexus, NLS Pharmaceutics, Axsome Therapeutics, Inc, Takeda, Pfizer, Avadel, Balance Therapeutics, and others
Key Narcolepsy Therapies: QUILIENCE (mazindol ER), Samelisant (SUVN-G3031), NLS-2, ALKS 2680, JZP258 (XYWAV), TS-091 5mg, JZP-258, SUVN-G3031, JNJ-17216498, Modafinil, sodium oxybate, THN102 300/3, Mazindol, AXS-12 (Reboxetine), TAK-861, PF-03654746, FT218, BTD-001, and others
The Narcolepsy epidemiology based on gender analyzed that females are more affected with narcolepsy (type1) than males
The Narcolepsy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Narcolepsy pipeline products will significantly revolutionize the Narcolepsy market dynamics.

Narcolepsy Overview

Narcolepsy is a chronic neurological disorder characterized by the brain’s inability to regulate sleep-wake cycles normally. People with narcolepsy experience excessive daytime sleepiness and uncontrollable episodes of falling asleep during the day, regardless of the amount of nighttime sleep. These sudden sleep attacks can occur during any type of activity.

Get a Free sample for the Narcolepsy Market Report:

https://www.delveinsight.com/report-store/narcolepsy-market

Narcolepsy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Narcolepsy Epidemiology Segmentation:

The Narcolepsy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Diagnosed Prevalent Cases of Narcolepsy in the 7MM
Subtype-specific Diagnosed Prevalent Cases of Narcolepsy in the 7MM
Age-specific Diagnosed Prevalent Cases of Narcolepsy in the 7MM
Treated Cases of Narcolepsy in the 7MM

Download the report to understand which factors are driving Narcolepsy epidemiology trends @ Narcolepsy Epidemiology Forecast

Narcolepsy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Narcolepsy market or expected to get launched during the study period. The analysis covers Narcolepsy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Narcolepsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Narcolepsy Therapies and Key Companies

QUILIENCE (mazindol ER): NLS Pharmaceutics
Samelisant (SUVN-G3031): Suven Life Sciences
NLS-2: NLS Pharmaceutics
ALKS 2680: Alkermes, Inc.
JZP258 (XYWAV): Jazz Pharmaceuticals
TS-091 5mg: Taisho Pharmaceutical
JZP-258: Jazz Pharma
SUVN-G3031: Suven Life Sciences Limited
JNJ-17216498: Alza Corporation, DE, USA
Modafinil: Cephalon
sodium oxybate: Orphan Medical
THN102 300/3: Theranexus
Mazindol: NLS Pharmaceutics
AXS-12 (Reboxetine): Axsome Therapeutics, Inc
TAK-861: Takeda
PF-03654746: Pfizer
FT218: Avadel
BTD-001: Balance Therapeutics

Discover more about therapies set to grab major Narcolepsy market share @ Narcolepsy Treatment Market

Narcolepsy Market Strengths

Many pharmaceutical companies are continuously researching and innovating the treatment regimens for eradicating the current unmet needs in narcolepsy.
The increasing prevalence of narcolepsy, for instance, knee pain associated with osteoarthritis, is primarily contributed by the increase in the aging population that will likely impact the market in the near future

Narcolepsy Market Opportunities

Identify potential therapeutic targets and strategies for improving quality of life, and restore functional levels of those who suffer from Narcolepsy
To understand the transition from acute to narcolepsy, how peripheral and central sensitization is manifested, and how they can be assessed

Scope of the Narcolepsy Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Narcolepsy Companies: NLS Pharmaceutics, Alkermes, Inc., Jazz Pharmaceuticals, Taisho Pharmaceutical, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical, Theranexus, NLS Pharmaceutics, Axsome Therapeutics, Inc, Takeda, Pfizer, Avadel, Balance Therapeutics, and others
Key Narcolepsy Therapies: QUILIENCE (mazindol ER), Samelisant (SUVN-G3031), NLS-2, ALKS 2680, JZP258 (XYWAV), TS-091 5mg, JZP-258, SUVN-G3031, JNJ-17216498, Modafinil, sodium oxybate, THN102 300/3, Mazindol, AXS-12 (Reboxetine), TAK-861, PF-03654746, FT218, BTD-001, and others
Narcolepsy Therapeutic Assessment: Narcolepsy current marketed and Narcolepsy emerging therapies
Narcolepsy Market Dynamics: Narcolepsy market drivers and Narcolepsy market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Narcolepsy Unmet Needs, KOL’s views, Analyst’s views, Narcolepsy Market Access and Reimbursement

To know more about Narcolepsy companies working in the treatment market, visit @ Narcolepsy Clinical Trials and Therapeutic Assessment

Table of Contents

1. Narcolepsy Market Report Introduction

2. Executive Summary for Narcolepsy

3. SWOT analysis of Narcolepsy

4. Narcolepsy Patient Share (%) Overview at a Glance

5. Narcolepsy Market Overview at a Glance

6. Narcolepsy Disease Background and Overview

7. Narcolepsy Epidemiology and Patient Population

8. Country-Specific Patient Population of Narcolepsy

9. Narcolepsy Current Treatment and Medical Practices

10. Narcolepsy Unmet Needs

11. Narcolepsy Emerging Therapies

12. Narcolepsy Market Outlook

13. Country-Wise Narcolepsy Market Analysis (2020–2034)

14. Narcolepsy Market Access and Reimbursement of Therapies

15. Narcolepsy Market Drivers

16. Narcolepsy Market Barriers

17. Narcolepsy Appendix

18. Narcolepsy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Narcolepsy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts| Taisho Pharmaceutical, Jazz Pharma, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical

Marlon Becerra and the treatments setting trends in 2025

The evolution of oral health has seen remarkable progress in recent years, driven by cutting-edge technologies and a holistic approach to patient care. Within this framework, Marlon Becerra Dentistry has solidified its position in 2025 thanks to innovative treatments that combine quality, aesthetics, and precision.

The trust of both local and international patients has positioned Marlon Becerra’s clinics in Bogotá (Colombia) as a leading destination for complex dental procedures. Services such as orthodontics, dental implants, and dental veneers are transforming lives by restoring not only functionality but also confidence. This success reflects the vision and expertise of Dr. Marlon Becerra, a recognized figure in aesthetic dentistry in Colombia and Latin America.

Dental implants and veneers: advanced solutions for health and aesthetics

Tooth loss can significantly impact quality of life, affecting both eating habits and self-esteem. To address this need, dental implants have become a highly sought-after option for patients seeking top-quality solutions at competitive prices. These implants, combined with crowns made from high-quality materials, or the all-on-four technique, restore chewing ability and provide a natural appearance that boosts confidence.

At Marlon Becerra Dentistry, patients will find several options to restore their natural beauty. For those who have lost all their teeth in one jaw, the best option is the innovative All-on-4 technique. This technique uses four strategically placed implants that support the fixed dental prosthesis with modern materials, improving chewing ability and achieving a natural and harmonious smile.

On the other hand, fixed crowns on implants are an excellent alternative for patients who have not lost all their teeth, as they restore aesthetics and functionality in a personalized manner. In summary, both implants with fixed crowns and the All-on-4 technique restore chewing ability and provide a natural appearance, making patients feel more confident.

Similarly, dental veneers are an effective solution for correcting imperfections such as stains, small fractures, or gaps between teeth. Both porcelain veneers and high-aesthetic resin veneers guarantee a flawless smile. Porcelain veneers, preferred by foreign patients in particular, are in high demand because they are highly resistant to stains and offer superior durability. However, daily care and good habits on the part of the patient are key to maintaining their flawless appearance.

His meticulous planning ensures results that are not only aesthetic but also functional, reducing treatment times and enhancing patient comfort.

It is increasingly common for patients from the United States to travel to Colombia to undergo these treatments, attracted by the combination of affordable costs and superior, guaranteed results. Dr. Marlon Becerra’s unique approach stands out as a differentiating factor, blending artistry, functionality, and advanced techniques developed throughout his career, including contributions to cosmetic dentistry presented at New York University.

The confidence inspired by these procedures, supported by state-of-the-art materials and the expertise of an interdisciplinary team, has made the clinic the preferred destination for international patients. This approach not only offers aesthetic results, but also restores the ability to eat comfortably while achieving a healthy and uniquely beautiful smile.

Orthodontics and smile design for international patients

Orthodontic treatments have become a cornerstone at Marlon Becerra Dentistry in 2025, offering customized solutions for both young and adult patients. Options include traditional braces, self-ligating systems, and invisible aligners, which are particularly popular among American patients. These aligners allow treatments to continue remotely, a significant advantage for those who cannot remain in the country for extended periods.

Each case begins with a comprehensive diagnosis supported by advanced digital technology, such as high-precision intraoral scanners and 3D simulations. This meticulous planning ensures not only aesthetic but also functional results, reducing treatment time and improving patient comfort.

Smile design, which often includes professional teeth whitening as part of the process, combines aesthetic analysis with advanced techniques to achieve harmonious, natural-looking results that respect each patient’s facial proportions. Emphasis is also placed on preventive care to ensure long-lasting results.

The treatments developed at Marlon Becerra Odontología, focused on oral health and overall well-being, have become a benchmark in 2025 by transforming smiles and improving the quality of life of countless patients. Those interested in learning more about their services and patient experiences can visit the clinic’s YouTube channel.

Media Contact
Company Name: Odontología de Marlon Becerra- Colombia
Contact Person: Press Office
Email: Send Email
Country: United States
Website: https://www.marlonbecerra.co/en/dental-veneers/dental-veneers-smiles/

RIPK1 Inhibitor Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Sanofi, Genfleet Therapeutics, Rigel Pharma, GlaxoSmithKline, AbbVie, Sanofi

RIPK1 Inhibitor pipeline constitutes 10+ key companies continuously working towards developing 12+ RIPK1 Inhibitor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“RIPK1 Inhibitor Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the RIPK1 Inhibitor Market.

The RIPK1 Inhibitor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the RIPK1 Inhibitor Pipeline Report:

Companies across the globe are diligently working toward developing novel RIPK1 Inhibitor treatment therapies with a considerable amount of success over the years. RIPK1 Inhibitor Key players such as – Sanofi, Genfleet Therapeutics, Rigel Pharmaceuticals, GlaxoSmithKline, AbbVie, Sanofi, Voronoi, Boston Pharmaceuticals, Sironax, Nuevolution, and others, are developing therapies for the RIPK1 Inhibitor treatment

RIPK1 Inhibitor Emerging therapies such as – SAR443122, GFH312, R552, and others are expected to have a significant impact on the RIPK1 Inhibitor market in the coming years.
In May 2025, Accropeutics’ investigational drug has successfully met the primary objectives in a Phase 2 clinical trial for psoriasis conducted in China, leading the company to commit to accelerating the clinical advancement of its TYK2/JAK1 inhibitor, AC-201. In the trial, 145 Chinese patients with moderate to severe plaque psoriasis were administered one of three doses of AC-201 or a placebo. All dosing groups achieved the primary endpoint, with a significantly higher proportion of patients reaching a 75% improvement in their Psoriasis Area and Severity Score (PASI 75) at Week 12 compared to the placebo group.
In October 2024, Sanofi discontinued its Phase 2 clinical trial of oditrasertib, an experimental RIPK1 inhibitor, in patients with relapsing and progressive multiple sclerosis (MS) after the treatment did not achieve its primary objectives. Initiated early last year, the trial failed to demonstrate a significant reduction in neurofilament light chain (NfL) levels — a biomarker associated with neurodegeneration. Additionally, the therapy did not meet any major secondary endpoints, as noted in a recent SEC filing by Denali Therapeutics, Sanofi’s development partner.

RIPK1 Inhibitor Overview

A RIPK1 inhibitor is a type of drug that blocks the activity of Receptor-Interacting Serine/Threonine-Protein Kinase 1 (RIPK1) — an enzyme involved in regulating inflammation, cell death (especially necroptosis), and immune responses. Overactivation of RIPK1 has been linked to several diseases, including autoimmune disorders, neurodegenerative conditions, and inflammatory diseases. By inhibiting RIPK1, these drugs aim to reduce excessive inflammation and tissue damage, offering a promising therapeutic strategy for conditions like multiple sclerosis, Alzheimer’s disease, and psoriasis.

Get a Free Sample PDF Report to know more about RIPK1 Inhibitor Pipeline Assessment- https://www.delveinsight.com/sample-request/ripk1-inhibitor-pipeline-insight

Emerging RIPK1 Inhibitor Drugs Under Different Phases of Clinical Development Include:

SAR443122: Sanofi
GFH312: GenFleet Therapeutics
R552: Rigel Pharmaceuticals

RIPK1 Inhibitor Pipeline Therapeutics Assessment

RIPK1 Inhibitor Assessment by Product Type
RIPK1 Inhibitor By Stage and Product Type
RIPK1 Inhibitor Assessment by Route of Administration
RIPK1 Inhibitor By Stage and Route of Administration
RIPK1 Inhibitor Assessment by Molecule Type
RIPK1 Inhibitor by Stage and Molecule Type

DelveInsight’s RIPK1 Inhibitor Report covers around 12+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Download Sample PDF Report to know more about RIPK1 Inhibitor drugs and therapies

RIPK1 Inhibitor Pipeline Analysis:

The RIPK1 Inhibitor pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the RIPK1 Inhibitor treatment with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for RIPK1 Inhibitor Treatment.
RIPK1 Inhibitor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
RIPK1 Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the RIPK1 Inhibitor market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further RIPK1 Inhibitor product details are provided in the report. Download the RIPK1 Inhibitor pipeline report to learn more about the emerging RIPK1 Inhibitor therapies

Scope of RIPK1 Inhibitor Pipeline Drug Insight

Coverage: Global
Key RIPK1 Inhibitor Companies: Sanofi, Genfleet Therapeutics, Rigel Pharmaceuticals, GlaxoSmithKline, AbbVie, Sanofi, Rigel Pharmaceuticals, Voronoi, Boston Pharmaceuticals, Sironax, Nuevolution, and others
Key RIPK1 Inhibitor Therapies: SAR443122, GFH312, R552, and others
RIPK1 Inhibitor Therapeutic Assessment: RIPK1 Inhibitor current marketed and RIPK1 Inhibitor emerging therapies
RIPK1 Inhibitor Market Dynamics: RIPK1 Inhibitor market drivers and RIPK1 Inhibitor market barriers

Request for Sample PDF Report for RIPK1 Inhibitor Pipeline Assessment and clinical trials

Table of Contents

1	RIPK1 Inhibitor Report Introduction
2	RIPK1 Inhibitor Executive Summary
3	RIPK1 Inhibitor Overview
4	RIPK1 Inhibitor- Analytical Perspective In-depth Commercial Assessment
5	RIPK1 Inhibitor Pipeline Therapeutics
6	RIPK1 Inhibitor Late Stage Products (Phase II/III)
7	RIPK1 Inhibitor Mid Stage Products (Phase II)
8	RIPK1 Inhibitor Early Stage Products (Phase I)
9	RIPK1 Inhibitor Preclinical Stage Products
10	RIPK1 Inhibitor Therapeutics Assessment
11	RIPK1 Inhibitor Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	RIPK1 Inhibitor Key Companies
14	RIPK1 Inhibitor Key Products
15	RIPK1 Inhibitor Unmet Needs
16	RIPK1 Inhibitor Market Drivers and Barriers
17	RIPK1 Inhibitor Future Perspectives and Conclusion
18	RIPK1 Inhibitor Analyst Views
19	Appendix
20	About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: RIPK1 Inhibitor Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Sanofi, Genfleet Therapeutics, Rigel Pharma, GlaxoSmithKline, AbbVie, Sanofi

Jae Rae, Spiritual Healer to the Stars, Launches Exclusive ‘Head Healers Masterclass’ This Fall

The 6-week virtual course offers rare access to Jae Rae’s healing methods, with limited seats available starting September 21.

New York, NY – Aug 5, 2025 – Jae Rae Lamas, a gifted spiritual healer and intuitive whose clientele includes global icons such as Jennifer Lopez, Adriana Lima, and Maria Menounos, is proud to announce the launch of her brand-new online course, the Head Healers Masterclass. This exclusive six-week online program is designed to help spiritual practitioners, empaths, and energy workers realign with their purpose and deepen their healing practice — from the inside out.

“For the first time ever, I’ll be sharing the methods I use to examine the hearts, minds, and souls of my clients, and how I help guide them back to wholeness,” says Jae Rae. “This online course will also be a sacred space for healers’ spiritual growth and alignment. Healers need healing too, and during this course, I’ll teach them how to realign themselves while also showing them how to heal and assess others.”

Through weekly live virtual sessions, participants will receive exclusive teachings from Jae Rae on energy work, intuitive diagnostics, heart-centered rituals, and client assessment frameworks. The curriculum combines live virtual teachings with hands-on practices, offering both practical tools and energetic guidance to help healers unlock their own power and elevate their ability to serve others.“True self‑love, clarity, and alignment don’t happen overnight,” says Jae Rae. “Small, consistent steps compound into profound transformation.”

The Head Healers Masterclass begins Sept. 21, 2025, and is open to anyone 18 and older. Enrollment is now open, with limited virtual seats to maintain the intimacy of the group. The course investment is $3,400 — with flexible payment plans available — and a rare opportunity to receive direct guidance from one of the most sought-after intuitives in the world.

Enrollment is now open at https://jaeraelive.com/products/head-healers

Media Inquiries:

Jae Rae is available for interviews. To schedule a conversation or request additional press materials, please contact Amy Rosa at jaeraelive@gmail.com.

About Jae Rae

A healer of both celebrities and everyday people, Jae Rae has built a loyal following over her 20-year career, amassing more than 20,000 followers on Instagram and 63,000 on TikTok. She offers virtual consultations through her signature Vibe Your Life program, and is known for delivering eerily accurate insights that transcend the physical realm. Jae Rae is “the real deal,” J.Lo has said.

To learn more or reserve your seat in the Head Healers Masterclass, visit jaeraelive.com.

Media Contact
Company Name: Jae Rae Live
Contact Person: Amy Rosa
Email: Send Email
City: New York
State: NY
Country: United States
Website: http://jaeraelive.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Jae Rae, Spiritual Healer to the Stars, Launches Exclusive ‘Head Healers Masterclass’ This Fall

Award-Winning Author Michael Foster’s Magic in the Blood Delivers a Spellbinding YA Fantasy of Courage, Magic, and the Fight to Save a World

In Magic in the Blood: Book 3 of The Wild Side Trilogy, award-winning author Michael Foster captivates with a gripping young-adult fantasy packed with magic, heartbreak, and destiny, as a brave young heroine must unlock her hidden powers to save her beloved lake, and the world, from destruction.

Michael Foster is an award-winning author, Founder of Lakepoint Books, and a long-time creative force in the video game industry. Currently serving as a Global Account Manager at Sony Interactive Entertainment, Michael champions independent developers across the globe. For over three decades, he’s helped shape the PlayStation experience through deep industry relationships and a passion for storytelling.

An avid gamer, musician, and reader, Michael brings the same creative energy to his writing. He is the author of the Wild Side Trilogy (The Passage at Moose Beach, Finding the Lost, and Magic in the Blood), a young adult fantasy series inspired by the wild beauty of Warm Lake, Idaho, where he spent his childhood exploring the vast Boise National Forest. Those formative years as a free-range child continue to fuel his imagination, now enriched by watching his wife and daughter discover the same woods that once captivated him. Although his writing began as a hobby, it has become a deeply meaningful creative pursuit with his work captivating readers across the globe.

This one-on-one interview shares Michael’s background and experience writing Magic in the Blood, the third book in The Wild Side Trilogy.

Tell us about Magic in the Blood.

In Magic in the Blood, the epic conclusion to The Wild Side Trilogy, I bring Alicia’s journey full circle. Now 14, she must return to the magical realm she once escaped to seek The Ancients, guardians of powerful secrets that may help restore the barrier she unintentionally destroyed. With dark forces spilling into her world and an old enemy rising stronger than ever, Alicia discovers a haunting truth: the magic that runs through her veins could either save or doom everything she loves.

Set against the wild beauty of Idaho’s forests, this final chapter blends high-stakes adventure with emotional depth, exploring the power of courage, grief, and love. Alicia will need to face unwanted truths, despair, and pain to learn that, just maybe, love is more powerful than hate.

What inspired you to write Magic in the Blood?

Magic in the Blood was born from my desire to capture the wonder I felt as a child exploring the deep woods around my family’s cabin in Idaho. Those long summers, filled with towering trees, hidden trails, and endless possibilities, sparked my imagination as I wondered what mystical creatures I might find in hidden places, and continue to do so to this day. I wanted to pass on that sense of enchantment and curiosity on to a new generation of young readers, as well as adults.

Alicia, the 14-year-old heroine of the trilogy, is inspired by the strength, compassion, and quiet resilience of my mother. Her character is a tribute to the kind of love that protects, empowers, and endures. Writing this book was not only a creative journey, but a deeply personal one, and Magic in the Blood is, in many ways, a love letter to both nature and the powerful women who shape our lives.

How did your background and experience influence your writing?

Storytelling has always been at the heart of everything I do. As a lifelong book lover, I could never walk by a bookstore without stopping in and browsing. I was interested in writing at a young age, but as a musician, I spent more time writing songs than stories.

Working in the video game industry has opened up an entirely new dimension of storytelling for me. I’ve had the privilege of witnessing how rich, emotional narratives can unfold interactively, and that perspective deeply influenced how I approached my own writing.

In The Wild Side Trilogy, I blended these passions, music and storytelling, using music as a powerful force to help Alicia discover how strong she truly is.

What is one message you would like readers to remember?

If there’s one message I hope readers take with them, it’s this: stay curious. Never stop asking questions, seeking out the hidden wonders, and believing in the magic woven into the world around us. Let your imagination roam freely.

And above all, remember no matter how dark the path may seem, love is always stronger than hate.

Purchasing the Book

The Wild Side Trilogy has received positive reviews from well-known literary organizations, authors, and reviewers around the world. Reader’s Favorite writes, “Compelling and masterfully told, an absolute must-read for all lovers of adrenaline-packed action and magic steeped in mythology.” In addition, BlueInk Reviews writes, “YA readers looking for a warm-hearted lesson in love winning out over hate will not be disappointed.”

The books are available for sale on Amazon, Barnes & Noble, Apple iBooks, Kobo, Nook, and other online bookstores. Readers are encouraged to purchase their copy today: https://www.amazon.com/Magic-Blood-Wild-Trilogy-Three-ebook/dp/B0FHQ8Q7TK

To connect with Michael and learn more about his work, visit: https://lakepointbooks.com/. You can also find him on Facebook, X, and Instagram.

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Award-Winning Author Michael Foster’s Magic in the Blood Delivers a Spellbinding YA Fantasy of Courage, Magic, and the Fight to Save a World

Accurate Precious Metals Refineries Debuts Seamless Mail-In Service

People everywhere can now sell their precious metals, jewelry, diamonds, and more via this convenient and simple mail-in solution from Accurate Precious Metals Refineries

The team at Accurate Precious Metals Refineries is thrilled to announce the official launch of its all-new mail-in service, which allows people everywhere to conveniently sell their precious metals, jewelry, diamonds, watches, broken jewelry, and items to be verified for authenticity and value. This service makes it easier than ever for people who want to get cash for gold and more.

Accurate Precious Metals Refineries opened its doors in 2012, and has become known as a leader in precious metals since that time. Cutting out the middleman, Accurate Precious Metals Refineries is a direct refinery that makes selling and buying gold, silver, and more easier than ever. This direct-to-refinery model ensures that customers receive the highest possible payouts, offering a superior alternative to pawn shops and local jewelry buyers. Customers can sell via the mail-in service with complete confidentiality and enjoy a streamlined process that avoids the need for customers to carry cash or haul valuable items to sell.

“Turning precious metals into cash should be simple and stress free—that’s why, as the country’s most competitive and trusted direct refinery, supported by 5 star reviews, we’ve introduced this mail-in service. Customers will receive a completely confidential, fast, and secure experience: no city treks carrying around valuables or cash, just GIA-certified evaluations, flexible payouts, and peace of mind knowing you’re dealing with industry leaders who give you top dollar. We buy gold, and we buy silver,” said Tyler Tarrillo, COO.

With the new mail-in service, customers receive the height of care including free shipping. All shipping labels are provided to the customer, offering direct shipping straight to the Accurate Precious Metals Refineries facility. Customers can use any suitable box to fit their shipping needs to make the process that much easier. Accurate Precious Metals Refineries is committed to customer care and offers shipping supplies. Customers automatically receive free, high-quality shipping supplies sent directly to them for secure packaging if they prefer to not use their own box. All shipments are fully insured for peace of mind.

Accurate Precious Metals Refineries is committed to ensuring fair, transparent pricing at every turn. The team’s experts include GIA-certified staff for precise diamond grading and evaluation to offer the best value for customers sending in diamonds for appraisal and purchase. Advanced XRF x-ray machines at the facility ensure accurate metals testing and precious metal purity verification. In addition, Accurate Precious Metals Refineries is an official authorized dealer with the NGC offering expert coin grading and evaluation. The team also specializes in estates, offering ease in handling inherited items and simplifying the process with stress-free, quick payouts. Clients have stated that Accurate Precious Metals “makes it simple and stress free to sell my gold and sell my silver.”

Thus far, customers have left thousands of five-star reviews for Accurate Precious Metals Refineries, and the launch of the new mail-in service, based on customer demand, is sure to provide a viable alternative for people looking to sell their valuables securely and conveniently. Flexible payout options include check, Zelle, and PayPal for fast, easy payments.

“As one of the most competitive and trusted precious metals dealers in the country, backed by thousands of 5-star reviews, we’re excited to launch our mail-in service that cuts out middlemen and delivers maximum value directly to customers. Say goodbye to the anxiety of pawnshops—no more hauling valuables around the city; our confidential, fully insured process makes selling jewelry, diamonds, or estates fast, safe, and stress-free from home,” said Tarrillo.

Learn more now by visiting https://accuratepmr.com/we-buy/mail-in-your-jewelry/.

ABOUT ACCURATE PRECIOUS METALS REFINERIES

Accurate Precious Metals Refineries is a family owned and operated business offering trusted precious metals services. Follow on social media:

Twitter/X: @accuratePMR

Instagram: @accuratepmr

Facebook: @accuratepreciousmetals

YouTube: @AccuratePreciousMetals

TikTok: @accuratepmr

Media Contact
Company Name: Accurate Precious Metals Refineries
Contact Person: Tyler Tarrillo, COO
Email: Send Email
Phone: 503-400-5608
Country: United States
Website: https://accuratepmr.com/

The 7th Global Chinese Life Short Video Competition Shaoxing City Shangyu District and “Youth City” online talent experience plan was officially launched

On August 1st, the “Youth City” online experience officer program, an important part of the 7th Global Chinese Life Short Video Competition in Shangyu District of Shaoxing, came to a successful conclusion in Shangyu District of Shaoxing.

The event attracted a lineup of “City Ambassadors” comprising dozens of influencers and international students from Japan, Bangladesh, Yemen, Russia, Morocco, Kazakhstan, and other countries. Collaborating with mainstream media outlets including People’s Daily, Xinhua News Agency, China News Network, China.org.cn, China Daily, Chao News, and Yue Niu News, they followed meticulously planned routes to immerse themselves in Shangyu’s natural beauty, cultural heritage, and industrial vitality. Through their lenses and words, they captured vivid impressions of this “City of Youth,” leaving behind numerous memorable records.

The first stop was the Gabei wild vine base. A bunch of plump and juicy grapes hung on the branches, emitting an attractive fragrance. People walked under the grape vines and picked ripe grapes by hand to experience the fun of picking.

“I grew up in the countryside, so I’m interested in country life,” said Diess from Kazakhstan, who was picking as he spoke. “It was a fun experience. The countryside here is different from my hometown, and I want to come back for more.”

The Xie Jin’s Hometown and Jin Shengxing Studio offer visitors a unique exploration of cinematic artistry intersecting with regional cultural heritage. Here, meticulously recreated classic film sets showcase an architectural ensemble steeped in antiquity, harmoniously blending with vintage props that transport viewers into a world where light and shadow weave together to create timeless narratives.

Ema and Sasha from Morocco took the lead in improvising on stage. Some students changed into qipao, and their posture instantly blended with the scenery of the Republic of China, which was frozen into a picture across time and space.

At Shangpu Ciyuan Cultural Town, participants discovered the joy of crafting celadon ceramics by hand. Under the guidance of instructors, everyone rolled up their sleeves to try shaping the clay. Though initially clumsy, they gradually mastered the techniques through patient coaching, bringing one unique celadon prototype after another to life in their hands.

The Cao Eli 13th Lane Historical and cultural Block allows participants to feel the interplay of ancient and modern lifestyles. Dressed in Hanfu, they walk through the antique streets and experience various activities.

Anna from Russia said, “This is my second time to come to Shaoxing. It was a very interesting experience. I have learned Chinese and Chinese culture in Russia, and I can appreciate the charm of Chinese culture more in daily life after coming to China.”

The Hangzhou Bay Embodied Intelligence Innovation Center in Cao’ejiang Economic Development Zone showcased cutting-edge technologies injecting fresh momentum into urban development. At the intelligent robotics exhibition area, various robots with diverse functions skillfully performed tasks like material handling, assembly, and human interaction, eliciting continuous exclamations of amazement.

While listening to the robot’s explanation, the volunteers recorded the robot’s wonderful performance with their cameras; while the overseas students interacted with the intelligent robot curiously and experienced the convenience and fun brought by technology.

Stepping into the exhibition hall of Songxia Friendship Fenuo Umbrella Industry, visitors are immediately greeted by the innovative fusion of modern design. International students enthusiastically try out the products. When they learned that crafting a simple umbrella from design to finished product involves dozens of processes and incorporates modern technological elements like windproofing and waterproofing, everyone couldn’t help but give it a thumbs-up.

The students also experienced coloring umbrellas and drawing their favorite patterns.

The final stop of this immersive experience was set in Jiangnan. The elegant live scenery drew international students to snap photos and capture the light and shadow effects with their phones and cameras. Participants even got hands-on experience with traditional printing techniques, taking home their personalized artworks. Later, they boarded a painted pleasure boat to cruise around the lake, where the scenery along the banks shifted with the waves, creating a unique charm.

Through culturally rich yet interactive arrangements, this event helped creators explore Shangyu’s unique blend of tradition and modernity, harmonious integration of natural landscapes and cultural heritage. The “Youth City” Online Influencer Experience Program, a key component of the 7th Global Chinese Lifestyle Short Video Competition in Shaoxing’s Shangyu District, concluded successfully in Shaoxing on August 1st.

The event attracted a lineup of “City Ambassadors” comprising dozens of influencers and international students from Japan, Bangladesh, Yemen, Russia, Morocco, Kazakhstan, and other countries. Collaborating with mainstream media outlets including People’s Daily, Xinhua News Agency, China News Network, China.org.cn, China Daily, Chao News, and Yue Niu News, they followed a meticulously designed exploration route to immerse themselves in Shangyu’s natural beauty, cultural heritage, and industrial vitality. Through their lenses and words, they captured vivid impressions of this “City of Youth” in their works.

The Xie Jin’s Hometown and Jin Shengxing Studio offer visitors a unique exploration of cinematic artistry intersecting with regional cultural heritage. Here, meticulously recreated classic film sets showcase an architectural ensemble steeped in history alongside period-appropriate props, creating a magical immersion that transports viewers into the luminous narrative space of cinema.

Anna from Russia said, “This is my second time to come to Shaoxing. It was a very interesting experience. I have learned Chinese and Chinese culture in Russia, but after coming to China, I can feel the charm of Chinese culture more in daily life.”

Stepping into the exhibition hall of Songxia Friendship Fenuo Umbrella Co., Ltd., visitors are immediately captivated by the innovative fusion of modern design. International students enthusiastically try out various products. When learning that crafting a simple umbrella involves dozens of production steps and incorporates cutting-edge technologies like windproofing and waterproofing, they all give it a thumbs-up.

The students also experienced coloring umbrellas and drawing their favorite patterns on them.

The final stop of this immersive experience was set in Jiangnan. The elegant live scenery drew international students to snap photos and capture the light and shadow effects with their phones and cameras. Participants even got hands-on experience with traditional printing techniques, taking home their personalized artworks. Later, they boarded a painted pleasure boat to cruise around the lake, where the changing waters revealed picturesque landscapes along both banks, creating a unique charm.

Through culturally rich and interactive arrangements, this event helped creators uncover Shangyu’s unique character – where tradition coexists with modernity, landscapes harmonize with cultural heritage, and local culture blends with global influences. It produced a diverse portfolio of high-quality works including photography, writing, and short videos. The short video entries generated during the event will directly compete in the Global Chinese Lifestyle Short Video Competition, showcasing Shangyu’s vibrant practices in urban-rural integration and its comprehensive efforts to build a “Youth City”.

The Global Chinese Lifestyle Short Video Competition is dedicated to showcasing the vibrant lives of overseas Chinese communities, documenting China’s evolving development, and promoting the global dissemination of Chinese stories through dynamic visual storytelling. Since its inaugural edition in 2019, the competition has attracted participants from over 40 countries and regions. The Shangyu District of Shaoxing City has officially launched the 7th Global Chinese Lifestyle Short Video Competition submission campaign on July 4, with entries open until September 30,2025. Participants are encouraged to create works that align with the “City of Youth” theme, welcoming submissions from around the world.

An official from the Publicity Department of Shangyu District Committee stated that Shangyu, an ancient county with a youthful district, boasts profound cultural heritage, thriving industries, and vibrant vitality. The Global Chinese Lifestyle Short Video Competition serves as an international platform for showcasing urban image. We aim to promote Shangyu’s youthful vibe, global flair, and futuristic vibe as a “City of Youth” to the nation and worldwide through this platform. This initiative seeks to help more people discover, visit, and fall in love with Shangyu, ultimately enhancing its global reputation and appeal.

The unique ethos of “integrating local and international elements” has cultivated a diverse portfolio of high-quality works encompassing photography, writing, short videos, and more. During the event, short video entries will compete in the Global Chinese Lifestyle Short Video Contest, showcasing Shangyu’s integrated urban-industrial development and its dynamic efforts to build a “Youth City” through comprehensive practices.

The Global Chinese Lifestyle Short Video Competition is dedicated to showcasing the vibrant lives of overseas Chinese communities, documenting China’s evolving development, and promoting the global dissemination of Chinese stories through dynamic visual storytelling. Since its inaugural edition in 2019, the competition has attracted participants from over 40 countries and regions. The Shangyu District of Shaoxing City has officially launched the 7th Global Chinese Lifestyle Short Video Competition submission campaign on July 4, with entries open until September 30,2025. Participants are encouraged to create works that align with the theme of “City of Youth”, welcoming submissions from around the world.

An official from the Publicity Department of Shangyu District Committee stated that Shangyu, an ancient county with a youthful district, boasts profound cultural heritage, thriving industries, and vibrant vitality. The Global Chinese Lifestyle Short Video Competition serves as an international platform for showcasing urban image. We aim to promote Shangyu’s “Youthful City” identity—characterized by youthful energy, global appeal, and forward-looking vision—to the nation and worldwide through this platform. This initiative seeks to help more people discover, visit, and fall in love with Shangyu, ultimately enhancing its global reputation and recognition.

Media Contact
Company Name: State Grid Zhejiang Electric Power Co., Ltd
Contact Person: Mr. Luo
Email: Send Email
Country: China
Website: https://www.zj.sgcc.com.cn

Ewing Sarcoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Nanovalent Pharma, Oncomatryx, Valent Technologies, Cellectar Biosciences, Eisai Inc

Ewing Sarcoma pipeline constitutes 25+ key companies continuously working towards developing 25+ Ewing Sarcoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Ewing Sarcoma Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ewing Sarcoma Market.

The Ewing Sarcoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Ewing Sarcoma Pipeline Report:

Companies across the globe are diligently working toward developing novel Ewing Sarcoma treatment therapies with a considerable amount of success over the years. Ewing Sarcoma Key players such as – Nanovalent Pharmaceuticals, Oncomatryx, Valent Technologies, Cellectar Biosciences, Eisai Inc., Shanghai Pharmaceuticals Holding, Exelixis, Gradalis, Inc., and others, are developing therapies for the Ewing Sarcoma treatment

Ewing Sarcoma Emerging therapies such as – NV-101, OMTX-703, VAL-413, CLR 131, Eribulin mesylate, TK216, Cabozantinib, Vigil EWS, and others are expected to have a significant impact on the Ewing Sarcoma market in the coming years.
In July 2025, Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company developing treatments for challenging, high-impact cancers through GSK-3β inhibition, has announced the completion of the Phase 1 segment of its clinical trial (Actuate-1902). The study evaluated elraglusib as a monotherapy or in combination with irinotecan, irinotecan plus temozolomide, or cyclophosphamide plus topotecan in pediatric patients with relapsed cancers. Encouraging signs of efficacy were observed, especially in treatment-resistant Ewing Sarcoma (EWS), a rare soft tissue and bone tumor. Based on these results, the company plans to move forward with a Phase 2 trial involving children, adolescents, and adults with relapsed/refractory EWS.
In November 2024, The FDA awarded rare pediatric disease designation to elraglusib (9-ING-41), an innovative GSK-3β inhibitor, as a potential treatment for Ewing sarcoma. The investigational therapy is currently being assessed in the open-label, multicenter Phase 1/2 Actuate-1902 trial (NCT04239092), which is examining its safety and efficacy in pediatric patients with relapsed or refractory cancers, including Ewing sarcoma and related small round cell sarcomas.

Ewing Sarcoma Overview

Ewing sarcoma is a rare type of cancer that primarily affects the bones or soft tissues. It most commonly occurs in children and young adults, typically between the ages of 10 and 20, but it can also occur in older adults. Ewing sarcoma most often arises in the bones of the pelvis, thighs, upper arms, or chest wall.

Get a Free Sample PDF Report to know more about Ewing Sarcoma Pipeline Assessment-

https://www.delveinsight.com/report-store/ewing-sarcoma-pipeline-insight

Ewing Sarcoma Pipeline Therapeutics Assessment

Ewing Sarcoma Assessment by Product Type
Ewing Sarcoma By Stage and Product Type
Ewing Sarcoma Assessment by Route of Administration
Ewing Sarcoma By Stage and Route of Administration
Ewing Sarcoma Assessment by Molecule Type
Ewing Sarcoma by Stage and Molecule Type

DelveInsight’s Ewing Sarcoma Report covers around 25+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Emerging Ewing Sarcoma Drugs Under Different Phases of Clinical Development Include:

NV-101: Nanovalent Pharmaceuticals
OMTX-703: Oncomatryx
VAL-413: Valent Technologies
CLR 131: Cellectar Biosciences
Eribulin mesylate: Eisai Inc.
TK216: Shanghai Pharmaceuticals Holding
Cabozantinib: Exelixis
Vigil EWS: Gradalis, Inc.

Download Sample PDF Report to know more about Ewing Sarcoma drugs and therapies

Ewing Sarcoma Pipeline Analysis:

The Ewing Sarcoma pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the Ewing Sarcoma treatment with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ewing Sarcoma Treatment.
Ewing Sarcoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Ewing Sarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ewing Sarcoma market.

Further Ewing Sarcoma product details are provided in the report. Download the Ewing Sarcoma pipeline report to learn more about the emerging Ewing Sarcoma therapies

Ewing Sarcoma Pipeline Market Drivers

Rising awareness about Ewing Sarcoma and financial assistance programs
Demand for New and Effective Drugs

Ewing Sarcoma Pipeline Market Barriers

Lack of approved therapies for Ewing’s sarcoma
Absence of predictive biomarkers in Ewing’s sarcoma

Scope of Ewing Sarcoma Pipeline Drug Insight

Coverage: Global
Key Ewing Sarcoma Companies: Nanovalent Pharmaceuticals, Oncomatryx, Valent Technologies, Cellectar Biosciences, Eisai Inc., Shanghai Pharmaceuticals Holding, Exelixis, Gradalis, Inc., and others
Key Ewing Sarcoma Therapies: NV-101, OMTX-703, VAL-413, CLR 131, Eribulin mesylate, TK216, Cabozantinib, Vigil EWS, and others
Ewing Sarcoma Therapeutic Assessment: Ewing Sarcoma current marketed and Ewing Sarcoma emerging therapies
Ewing Sarcoma Market Dynamics: Ewing Sarcoma market drivers and Ewing Sarcoma market barriers

Request for Sample PDF Report for Ewing Sarcoma Pipeline Assessment and clinical trials

Table of Contents

1	Ewing Sarcoma Report Introduction
2	Ewing Sarcoma Executive Summary
3	Ewing Sarcoma Overview
4	Ewing Sarcoma- Analytical Perspective In-depth Commercial Assessment
5	Ewing Sarcoma Pipeline Therapeutics
6	Ewing Sarcoma Late Stage Products (Phase II/III)
7	Ewing Sarcoma Mid Stage Products (Phase II)
8	Ewing Sarcoma Early Stage Products (Phase I)
9	Ewing Sarcoma Preclinical Stage Products
10	Ewing Sarcoma Therapeutics Assessment
11	Ewing Sarcoma Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Ewing Sarcoma Key Companies
14	Ewing Sarcoma Key Products
15	Ewing Sarcoma Unmet Needs
16	Ewing Sarcoma Market Drivers and Barriers
17	Ewing Sarcoma Future Perspectives and Conclusion
18	Ewing Sarcoma Analyst Views
19	Appendix
20	About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ewing Sarcoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Nanovalent Pharma, Oncomatryx, Valent Technologies, Cellectar Biosciences, Eisai Inc

Chris Macaulay Makes Culture the Cornerstone of Growth at Killara Outdoors

Culture builds companies,” Macaulay says. “You can fake a product for a while. You can’t fake values.

For Chris Macaulay, CEO of Killara Outdoors, great businesses aren’t just built on strategy, product, or capital; they’re built on culture.

In the newly published article Culture as a Competitive Advantage: How Killara Outdoors CEO Chris Macaulay Is Redefining Leadership in the Outdoor Industry, the executive outlines his people-first blueprint for sustainable growth and why investing in culture is more than just a feel-good initiative.

“Culture builds companies,” Macaulay says. “You can fake a product for a while. You can’t fake values.”

Since taking the helm at Killara in 2023, Macaulay has overseen rapid growth across the company’s multi-brand portfolio. With offices in Texas, Colorado, and Hong Kong, Killara supports outdoor brands in the fishing, hunting, and lifestyle sectors; but it’s the company’s shared cultural operating system that’s driving the real momentum.

At Killara, culture isn’t confined to HR or annual surveys. It’s built into the cadence of the business: from structured onboarding processes and decentralized decision-making to monthly “Culture Builds” that reinforce trust, transparency, and team alignment across brands and departments.

“If you don’t define culture, it defines itself; and usually not in a good way,” Macaulay notes.

Killara’s values-led approach is a breath of fresh air in an industry where founder burnout, post-acquisition dissonance, and communication breakdowns are common. By prioritizing clarity, shared purpose, and personal growth, Macaulay and his team have created an environment where leadership development and operational excellence go hand-in-hand.

“We’re not just scaling products; we’re scaling people,” he adds. “If your team is aligned, focused, and healthy, they’ll find ways to win; especially when things get hard.”

The article highlights how Killara’s culture-first model is influencing a new wave of operators who want to grow with purpose, not just profit. In a market that often prioritizes speed and scale at the cost of soul, Killara is building something different; and lasting.

Read the full article:

killara.com/blog/culture-as-a-competitive-advantage-how-killara-outdoors-ceo-chris-macaulay-is-redefining-leadership-in-the-outdoor-industry

Media Contact
Company Name: Killara Outdoors
Email: Send Email
Address:180 State Street, 201
City: Southlate
State: Texas 76092
Country: United States
Website: https://killara.com

Corporate Window Films Expands Protective Offerings with Philadelphia Security Tint

Corporate Window Films introduces a new solution that adds safety, style, and strength to windows across homes, offices, and commercial vehicles.

Feasterville, PA – August 5, 2025 – Corporate Window Films announces the expansion of its protective solutions with the launch of its specialized Philadelphia Security Tint, now available to commercial and residential clients throughout the region. This advanced window film delivers increased safety and durability for buildings and vehicles by reinforcing glass against break-ins, storm damage, and everyday impact.

With growing concerns over property security in urban and suburban areas, the demand for effective glass protection continues to rise. Corporate Window Films addresses this need by offering a high-performance tinting solution that adds a critical layer of defense without compromising appearance or visibility. Designed to withstand harsh conditions, the product supports property owners who value both aesthetics and safety.

A spokesperson said, “We developed the Security Tint to meet the real needs of people who want to protect their homes or commercial spaces from unexpected threats. This is the best window tint in Philadelphia for customers who prioritize safety and style without sacrificing natural light.”

The company’s new security film complements its full line of visual branding and energy-efficient tint products, including Philadelphia Commercial Graphics, custom film design, and architectural applications. With decades of experience in the region, Corporate Window Films brings practical expertise to every project, whether it involves storefronts, office complexes, or homes. Homeowners can also consult directly with the company to better understand the home window tint Philadelphia cost and how this investment contributes to both safety and energy savings.

In addition to architectural installations, Corporate Window Films serves business owners and logistics professionals with high-impact solutions for vehicles. The team integrates security film into its Commercial Fleet Vehicle Signage Philadelphia services, offering clients protection and visibility on the road. This dual-purpose approach supports both branding and asset protection for fleet managers.

“Fleet owners often ask how they can protect their drivers and vehicles without disrupting their brand identity. Our integrated solution solves both challenges with one application. It’s practical, strong, and reflects the professionalism our clients expect,” the spokesperson said.

Residents and business owners looking for Philadelphia window film near me will now have direct access to consultations, tailored recommendations, and certified installation services from Corporate Window Films. The company continues to set the standard for quality and reliability in the regional window film industry.

About Company:

Corporate Window Films has established itself as a leader in the window film industry, proudly serving the Philadelphia and beyond. Visit https://corporatewindowfilm.com/

Media Contact
Company Name: Corporate Window Films
Contact Person: Jared Yampolsky
Email: Send Email
Phone: +1 215-901-4294
Address:18 Indian Path Lane
City: Feasterville
State: PA
Country: United States
Website: https://corporatewindowfilm.com/